Policy | August 27, 2025
GST rejig may impact competitiveness of medical devices: AiMeD
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages
Unfortunate to see PM’s ‘Make in India’ dream being bulldozed
Medical Device Policy is a progressive step in propelling the country towards Atmanirbharta in the heavily import dependent Medical Device Sector
The Niti Aayog and the DoP had listed a few factors that were leading to a 10-15% disability factor to be globally competitive
India imported medical devices worth Rs. 63,200 crore in 2021-22, up 41% from Rs. 44,708 crore in 2020-21
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
Subscribe To Our Newsletter & Stay Updated
